News PolyPid Ltd.

Equities

PYPD

IL0011326795

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-17 pm EDT			5-day change	1st Jan Change
4.315 ^USD	-2.82%		-9.02%	+13.55%

May. 08	Transcript : PolyPid Ltd., Q1 2024 Earnings Call, May 08, 2024
May. 08	PolyPid Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

POLYPID : AMENDED AND RESTATED 2012 SHARE OPTION PLAN - Form 6-K	May. 17	PU
Transcript : PolyPid Ltd., Q1 2024 Earnings Call, May 08, 2024	May. 08
PolyPid Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results	May. 08	AQ
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections	May. 01	AQ
PolyPid to Participate in Citizens JMP Life Sciences Conference	May. 01	AQ
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections	Apr. 30	AQ
PolyPid Ltd. Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections	Apr. 30	CI
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024	Apr. 24	AQ
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference	Feb. 28	AQ
Transcript : PolyPid Ltd., Q4 2023 Earnings Call, Feb 14, 2024	Feb. 14
PolyPid Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 14	CI
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 14	AQ
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial	Feb. 12	AQ
PolyPid Ltd. Announces Enrollment of the 100th Patient in the Ongoing Shield II Phase 3 Trial	Feb. 12	CI
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024	Jan. 31	AQ
PolyPid Ltd. announced that it has received $35.01012 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc.	Jan. 21	CI
PolyPid Enters Into $16.2 Million Private Placement Deal	Jan. 05	MT
PolyPid Announces Private Placement for $16 Million in Gross Proceeds	Jan. 04	AQ
PolyPid Ltd. announced that it expects to receive $16.216011 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc. and other investors	Jan. 03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News PolyPid Ltd.

Equities

PYPD

IL0011326795

Summary

Filters